54 Recruiting Studies Using Tremelimumab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Tremelimumab
SIRT With Tremelimumab and Durvalumab for Resectable HCC
📍 Cedars-Sinai Medical Center — Los Angeles, California
Resectable Hepatocellular Carcinoma
View Study & Checklist ➔Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
📍 University of California, San Diego — San Diego, California
Hepatocellular Carcinoma
View Study & Checklist ➔Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
📍 City of Hope Medical Center — Duarte, California
BCLC Stage B Hepatocellular Carcinoma
View Study & Checklist ➔Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
📍 Research Site — Phoenix, Arizona
Non Small Cell Lung Cancer NSCLC
View Study & Checklist ➔TheraSphere With Durvalumab and Tremelimumab for HCC
📍 University of California San Diego — San Diego, California
Hepatocellular Carcinoma
View Study & Checklist ➔Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
📍 Tom Baker Cancer Centre — Calgary, Alberta
Solid Malignancies
View Study & Checklist ➔Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
📍 Research Site — Tucson, Arizona
Small Cell Lung Cancer
View Study & Checklist ➔Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
📍 UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
Fallopian Tube Endometrioid Tumor
View Study & Checklist ➔Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Bladder Urothelial Carcinoma
View Study & Checklist ➔Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
📍 Research Site — Birmingham, Alabama
Unresectable Locally Advanced Urothelial Cancer
View Study & Checklist ➔Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Metastatic Malignant Female Reproductive System Neoplasm
View Study & Checklist ➔Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Germ Cell Tumor
View Study & Checklist ➔Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
📍 Research Site — Orange, California
Muscle Invasive Bladder Cancer
View Study & Checklist ➔Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
📍 Research Site — Los Angeles, California
Hepatocellular Carcinoma
View Study & Checklist ➔Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
📍 Research Site — Birmingham, Alabama
Small Cell Lung Carcinoma Extensive Disease
View Study & Checklist ➔Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Small Cell Lung Cancer Extensive Stage
View Study & Checklist ➔A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
📍 Research Site — Phoenix, Arizona
Hepatocellular Carcinoma
View Study & Checklist ➔Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
📍 Research Site — Scottsdale, Arizona
Unresectable Pleural or Peritoneal Malignant Mesothelioma
View Study & Checklist ➔A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
📍 Research Site — Beverly Hills, California
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Metastatic Colorectal Carcinoma
View Study & Checklist ➔Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
📍 Research Site — Los Angeles, California
Urothelial Cancer
View Study & Checklist ➔Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Esophageal Adenocarcinoma
View Study & Checklist ➔Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
📍 Cliniques Universitaires Saint-Luc — Brussels,
Oropharyngeal Squamous Cell Carcinoma
View Study & Checklist ➔Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
📍 Campbelltown Hospital — Campbelltown, New South Wales
Lung Cancer Metastatic
View Study & Checklist ➔Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Hepatocellular Cancer
View Study & Checklist ➔PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
📍 Moffitt Cancer Center — Tampa, Florida
Ovarian Cancer
View Study & Checklist ➔Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
📍 Research Site — La Jolla, California
Advanced Hepatocellular Carcinoma
View Study & Checklist ➔Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
📍 M D Anderson Cancer Center — Houston, Texas
Hydronephrosis
View Study & Checklist ➔Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
📍 Research Site — Birmingham, Alabama
Hepatocellular Carcinoma
View Study & Checklist ➔An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
📍 Mercy Medical Center - Medline Healthcare Services LLC — Baltimore, Maryland
Unresectable Hepatocellular Carcinoma
View Study & Checklist ➔Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
📍 BCG Oncology — Phoenix, Arizona
Urothelial Carcinoma
View Study & Checklist ➔Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
📍 Research Site — Scottsdale, Arizona
Non-Small-Cell Lung Carcinoma NSCLC
View Study & Checklist ➔Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
📍 Massachusetts General Hospital — Boston, Massachusetts
Hepatocellular Carcinoma
View Study & Checklist ➔A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Combined Hepatocellular and Cholangiocarcinoma
View Study & Checklist ➔Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
📍 OHSU Knight Cancer Institute — Portland, Oregon
Locally Advanced Hepatocellular Carcinoma
View Study & Checklist ➔Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
📍 University of Kansas Cancer Center — Westwood, Kansas
Gastric Cancer
View Study & Checklist ➔A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
📍 City of Hope /ID# 261468 — Duarte, California
Hepatocellular Carcinoma
View Study & Checklist ➔Durvalumab and Tremelimumab in Resectable HCC
📍 University Health Network — Toronto, Ontario
Hepatocellular Carcinoma
View Study & Checklist ➔Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
📍 UT Health San Antonio — San Antonio, Texas
Hepatocellular Carcinoma
View Study & Checklist ➔Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
📍 Stanford University — Stanford, California
Non Small Cell Lung Cancer
View Study & Checklist ➔Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
📍 Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Carcinoma, Non-Small Cell Lung
View Study & Checklist ➔Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
📍 Grady Health System — Atlanta, Georgia
Advanced Hepatocellular Carcinoma
View Study & Checklist ➔Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
📍 Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
Advanced Hepatocellular Carcinoma
View Study & Checklist ➔Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
📍 SKCCC Johns Hopkins Medical Institution — Baltimore, Maryland
Biliary Tract Cancers
View Study & Checklist ➔Targeted Pathway Inhibition in Patients With Pancreatic Cancer
📍 OHSU Knight Cancer Institute — Portland, Oregon
Locally Advanced Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
📍 Research Site — Phoenix, Arizona
Hepatocellular Carcinoma
View Study & Checklist ➔Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Hepatocellular Carcinoma
View Study & Checklist ➔Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
📍 CTCA at Western Regional Medical Center — Goodyear, Arizona
Lung Non-Small Cell Carcinoma
View Study & Checklist ➔A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
📍 Cross Cancer Institute — Edmonton, Alberta
Cancer
View Study & Checklist ➔Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
📍 Mayo Clinic in Florida — Jacksonville, Florida
Locally Advanced Intrahepatic Cholangiocarcinoma
View Study & Checklist ➔Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
📍 Cross Cancer Institute — Edmonton, Alberta
Pancreatic Cancer
View Study & Checklist ➔ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
Solid Tumor, Adult
View Study & Checklist ➔Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
📍 University of California, San Francisco — San Francisco, California
Advanced Hepatocellular Carcinoma
View Study & Checklist ➔Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
📍 UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist ➔